AGN Feedback in SDSS-IV MaNGA: AGNs have Suppressed Central Star Formation Rates

Despite the importance of feedback from active galactic nuclei (AGNs) in models of galaxy evolution, observational constraints on the influence of AGN feedback on star formation remain weak. To this end, we have compared the star formation trends of 279 low-redshift AGN galaxies with 558 inactive control galaxies using integral field unit spectroscopy from the SDSS-IV MaNGA survey. With a Gaussian process-based methodology, we reconstruct nonparametric star formation histories in spatially resolved spaxels covering the face of each galaxy. Based on galaxy-wide star formation rates (SFRs) alone, we find no obvious signatures of AGN feedback. However, the AGN galaxies have significantly suppressed central (kiloparsec-scale) SFRs, lying up to a factor of $2$ below those of the control galaxies, providing direct observational evidence of AGN feedback suppressing star formation. The suppression of central SFRs in the AGN galaxies began in the central regions ${\sim} 6$ Gyr ago (redshift $z {\sim} 0.7$), taking place over a few gigayears. A small subset of the AGN galaxies were rapidly driven to quiescence shortly before being observed (in the last $500$ Myr), potentially indicating instances of AGN-driven feedback. More frequently, however, star formation continues in the AGN galaxies, with suppression primarily in the central regions. This is suggestive of a picture in which integrated (Gyr-timescale) AGN feedback can significantly affect central star formation, but may be inefficient in driving galaxy-wide quenching in low-redshift galaxies, instead leaving them in the green valley.Comment: 22 pages, 15 figures. Accepted for publication in Ap

International recommendations for an effective control of head louse infestations

Head louse infestations continue to be a concern of public health in most countries, including the most developed ones. The present recommendations are intended to inform and stress the role and impact of the different authorities, institutions, industry, and the public in the control of head lice in order to reduce the prevalence of this parasite. We encourage health authorities to pursue more effective methods to correctly identify such infestations, and evaluate existing and new pediculicides, medical devices, louse repellents, and louse- and nit-removal remedies. Pediculicides and medical devices must have verifiable claims in the instructions for use and should be tested periodically to document current levels of resistance by lice to the active ingredients and to the formulated products. Where the prevalence of lice is claimed to be epidemic, children should be periodically evaluated objectively to document the actual level of prevalence. Continuing education for health providers and the general population promises to correct misinformation regarding the biology, prevention, and management of lice. Parents should regularly inspect their children for head lice and treat as necessary. Health authorities are encouraged to eliminate policies and practices that rely upon school exclusion as a means to reduce incidence and prevalence, e.g., the ‘no-nit’ policy which lacks scientific justification, and are counterproductive to the health and welfare of childrenFil: Mumcuoglu, Kosta Y.. The Hebrew University of Jerusalem; IsraelFil: Pollack, Richard J.. Harvard University; Estados UnidosFil: Reed, David L.. University Of Florida. Florida Museum Of History; Estados UnidosFil: Barker, Stephen C.. University of Queensland; AustraliaFil: Gordon, Shirley. Florida Atlantic University; Estados UnidosFil: Toloza, Ariel Ceferino. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones Científicas y Técnicas para la Defensa. Centro de Investigación de Plagas e Insecticidas; ArgentinaFil: Picollo, Maria Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones Científicas y Técnicas para la Defensa. Centro de Investigación de Plagas e Insecticidas; ArgentinaFil: Taylan Ozkan, Aysegul. Hitit University; Turquía. Near East University; ChipreFil: Chosidow, Olivier. Hôpital Henri Mondor; FranciaFil: Habedank, Birgit. German Environment Agency; AlemaniaFil: Ibarra, Joanna. Community Hygiene Concern; Reino UnidoFil: Meinking, Terri L.. Global Health Associates of Miami; Estados UnidosFil: Vander Stichele, Robert H.. Heymans Institute of Pharmacology; Bélgic

Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience.

BACKGROUND: The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile, suggesting it may be advantageous in older patients at greater risk of treatment-related complications. However, there is a paucity of data exploring the outcomes of vedolizumab in this group. Our objective was to determine the clinical effectiveness and safety of vedolizumab in older IBD patients within a real-world multicenter UK cohort. METHODS: A retrospective review of electronic records across 6 UK hospitals was undertaken to evaluate the clinical effectiveness and safety outcomes of vedolizumab in IBD patients aged ≥60 at start of therapy. Rates of clinical response, remission and corticosteroid-free remission were assessed at weeks 14 and 52, using validated clinical indices, and were compared to historical controls from real-world vedolizumab-treated cohorts unstratified by age. RESULTS: Of 74 patients aged 60 years or above (median 66 years), 48 were included in our effectiveness analysis (29 ulcerative colitis, 19 Crohn's disease). Rates of clinical response, remission and corticosteroid-free remission at week 14 were 64%, 48% and 30%, respectively. By week 52, the rates of clinical response, remission, and corticosteroid-free remission were 52%, 38%, and 32%, respectively. Six (8%) patients experienced adverse effects. Effectiveness and safety outcomes were comparable to those of age-unstratified vedolizumab-treated cohorts. CONCLUSION: Our 1-year outcome data suggests that vedolizumab is safe and effective in older IBD patients and broadly comparable to cohorts unselected by age

Baş biti enfestasyonlarının etkin kontrolü için uluslararası tavsiyeler

Baş biti enfestasyonları, en gelişmiş olanlar da dâhil olmak üzere çoğu ülkede halk sağlığını ilgilendiren bir sorun olmaya devam etmektedir. Makalede sunulan tavsiyeler, bu parazitin prevalansını azaltmak amacıyla baş biti kontrolünde farklı otoritelerin, kurumların, endüstrinin ve kamunun rollerini ve etkilerini vurgulamayı ve bilgilendirmeyi amaçlamaktadır. Sağlık yetkililerini, bu tür enfestasyonların doğru şekilde tespit edilmesi; mevcut ve yeni pedikülositler, tıbbi cihazlar, repellentler, bit ve yumurta giderici ürünlerin değerlendirilmesi amacıyla daha etkili yöntemler iz açıklamalara sahip olmalı ayrıca aktif bileşenlere ve formüle ürünlere karşı bitlerin direnç seviyelerinin mevcut durumunu belgelemek için periyodik olarak test edilmelidir. Bit yaygınlığının salgın düzeyine ulaştığı iddiaları ortaya atıldığında, gerçek yaygınlık düzeyinin kanıtlanması amacıyla çocuklar periyodik aralıklarla objektif olarak değerlendirilmelidir. Sağlık hizmeti sunanlar ve toplum geneli için düzenlenen sürekli eğitimlerle bitlerin biyolojisi, önlenmesi ve kontrolü konusundaki yanlış bilgilerin düzeltilmesi sağlanabilir. Ebeveynler, çocuklarını baş biti açısından düzenli olarak kontrol etmeli ve gerektiğinde tedavi etmelidir. Sağlık yetkilileri, vakaları ve yaygınlığı azaltmada bir araç olarak kullanılan ancak bilimsel gerekçesi olmadığı gibi çocukların sağlığı ve huzuruna da ters etki yapan “sirkeye geçit yok- no-nit politikası” tarzında çocukları okuldan uzaklaştırmaya dayalı politika ve uygulamaların ortadan kaldırılması için mücadele etmelidir.lemeye teşvik etmeyi umuyoruz. Pedikülositler ve tıbbi cihazlar, kullanım talimatlarında doğrulanabilirHead louse infestations continue to be a concern of public health in most countries, including the most developed ones. The present recommendations are intended to inform and stress the role and impact of the different authorities, institutions, industry, and the public in the control of head lice in order to reduce the prevalence of this parasite. We encourage health authorities to pursue more effective methods to correctly identify such infestations, and evaluate existing and new pediculicides, medical devices, louse repellents, and louse and nit-removal remedies. Pediculicides and medical devices must have verifiable claims in the instructions for use and should be tested periodically to document current levels of resistance by lice to the active ingredients and to the formulated products. Where the prevalence of lice is claimed to be epidemic, children should be periodically evaluated objectively to document the actual level of prevalence. Continuing education for health providers and the general population promises to correct misinformation regarding the biology, prevention, and management of lice. Parents should regularly inspect their children for head lice and treat as necessary. Health authorities are encouraged to eliminate policies and practices that rely upon school exclusion as a means to reduce incidence and prevalence, e.g., the ‘no-nit’ policy which lacks scientific justification, and are countFil: Mumcuoğlu, Kosta Y.. The Hebrew University; IsraelFil: Pollack, Richard J.. Harvard University. Harvard School of Public Health; Estados UnidosFil: Reed, David. University Of Florida. Florida Museum Of History. Departamento Of Biology; Estados UnidosFil: Barker, Stephen. The University of Queensland; AustraliaFil: Gordon, Shirley. Florida Atlantic University (fau);Fil: Toloza, Ariel Ceferino. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Investigación y Desarrollo Estratégico para la Defensa. Ministerio de Defensa. Unidad de Investigación y Desarrollo Estratégico para la Defensa; ArgentinaFil: Picollo, Maria Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Investigación y Desarrollo Estratégico para la Defensa. Ministerio de Defensa. Unidad de Investigación y Desarrollo Estratégico para la Defensa; ArgentinaFil: Taylan Özkan, Ayşegül. Tobb University Of Economics And Technology; TurquíaFil: Chosidow, Olivier. Hopital Henri Mondor; FranciaFil: Habedank, Birgit. German Environment Agency; AlemaniaFil: Ibarra, Joanna. Community Hygiene Concern; Reino UnidoFil: Meinking, Terri L.. Global Health Association Of Miami; Estados UnidosFil: Stichele, Robert Vander. University of Ghent; Bélgic

Sixteen diverse laboratory mouse reference genomes define strain-specific haplotypes and novel functional loci.

We report full-length draft de novo genome assemblies for 16 widely used inbred mouse strains and find extensive strain-specific haplotype variation. We identify and characterize 2,567 regions on the current mouse reference genome exhibiting the greatest sequence diversity. These regions are enriched for genes involved in pathogen defence and immunity and exhibit enrichment of transposable elements and signatures of recent retrotransposition events. Combinations of alleles and genes unique to an individual strain are commonly observed at these loci, reflecting distinct strain phenotypes. We used these genomes to improve the mouse reference genome, resulting in the completion of 10 new gene structures. Also, 62 new coding loci were added to the reference genome annotation. These genomes identified a large, previously unannotated, gene (Efcab3-like) encoding 5,874 amino acids. Mutant Efcab3-like mice display anomalies in multiple brain regions, suggesting a possible role for this gene in the regulation of brain development

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life

Global urban environmental change drives adaptation in white clover

Urbanization transforms environments in ways that alter biological evolution. We examined whether urban environmental change drives parallel evolution by sampling 110,019 white clover plants from 6169 populations in 160 cities globally. Plants were assayed for a Mendelian antiherbivore defense that also affects tolerance to abiotic stressors. Urban-rural gradients were associated with the evolution of clines in defense in 47% of cities throughout the world. Variation in the strength of clines was explained by environmental changes in drought stress and vegetation cover that varied among cities. Sequencing 2074 genomes from 26 cities revealed that the evolution of urban-rural clines was best explained by adaptive evolution, but the degree of parallel adaptation varied among cities. Our results demonstrate that urbanization leads to adaptation at a global scale

Restricciones teóricas de la justicia contencioso administrativa para la declaratoria de responsabilidad extracontractual del Estado por error jurisdiccional

El presente trabajo tuvo como propósito realizar la identificación y análisis de las restricciones que se presentan teóricamente para la declaratoria de responsabilidad extracontractual del Estado por error jurisdiccional, puesto que existe incertidumbre sobre el tema. Para cumplir este propósito se realizó una investigación cualitativa con enfoque empírico analítico, tomando como fuentes de información y estudio la Constitución Política de Colombia, la Ley Estatutaria de Administración de Justicia, la jurisprudencia de la Corte Constitucional, la jurisprudencia del Consejo de Estado y algunos criterios doctrinales. El análisis de esta información presentó como resultado la existencia de una serie de restricciones tanto de carácter legal como jurisprudencial, cuyo origen se encuentra en la ley 270 de 1996 y en la sentencia de la Corte Constitucional C – 037 de 1996, que limitan la posibilidad de declarar al Estado responsable por los perjuicios causados por un error jurisdiccional en unos determinados eventos. A esto se debe sumar que en las providencias del Consejo de Estado se ha presentado un rechazo hacía dichas limitantes, lo cual se ha sustentado en diversas construcciones argumentativas. Desde este panorama, se pudo formular e individualizar las restricciones que se presentan para la declaratoria de la mencionada forma de responsabilidad, desde múltiples perspectivas. Por último, se planteó una evaluación de dichas restricciones, teniendo como punto de referencia principal la Carta Suprema, con el fin de proponer que el ordenamiento jurídico colombiano alberga una aplicación alternativa de las normas que regulan el tema